Abstract: The present disclosure provides 1) crystalline Form A of Compound 1a or a tautomer thereof; 2) crystalline Forms D and E of Compound 1b, or a tautomer and/or hydrate thereof; and 3) co-crystalline Form C of Compound 1 and Compound 1b, or a tautomer thereof, each of which is represented by the formula: (Compound 1a), (Compound 1b), (Compound 1), or a tautomer thereof. The present disclosure also provides methods for preparing crystalline Form A of Compound 1a. Compositions including one or more of crystalline Forms A, D, E, and C and methods of treating a disease or disorder (e.g., primary hyperoxaluria (PHI), kidney and/or bladder stones, hyperoxaluria) thereof are also provided herein. Further, the present disclosure provides processes for preparing compounds (e.g., Compound 1, Compound 1b, and formula (I)—an ester of Compound 1).

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

Abstract: The present invention provides anti-plazomicin antibodies and methods of use thereof, e.g., in determining levels of plazomicin in samples from human patients undergoing treatment with plazomicin. Such antibodies are useful, for example, in monitoring plazomicin levels during treatment for an infectious disease.